Circulating dipeptidyl peptidase 3 (cDPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. A new study by Florian A. Wenzl et al. published in the European Heart Journal identified cDPP3 as a novel marker of cardiogenic shock (CS) and increased mortality in patients with (ACS).
The authors assessed plasma cDPP3 levels at baseline and 12–24 h after presentation in patients with ACS prospectively enrolled into the multi-centre SPUM-ACS study (n = 4787). Circulating DPP3 levels were independently associated with in-hospital CS, 30-day mortality and 1-year mortality after adjustment for established risk factors and risk scores. Compared to values within the normal range, persistently elevated cDPP3 levels at 12–24 h were associated with 13.4-fold increased 30-day mortality risk and 5.8-fold increased 1-year mortality risk.
Circulating DPP3 provides prognostic information beyond established risk factors and is a potential therapeutic target in patients with ACS.
Editorial Article in the European Heart Journal
Presentation at the ESC Congress 2023